تحت رعاية سمو الشـــيخ حــمــدان بن راشـــد آل مــكـتوم، نائب حاكم دبي، وزير المالية، رئيس هيئة الصحة بدب
Under the patronage of His Highness Sheikh Hamdan bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance, UAE and President of Dubai Health Authority

Don’t miss this Worldwide Diabetes Virtual Webinar in conjunction with the International Family Medicine Conference and Exhibition

(CME accreditation by DHA in process)

The treatment of type 2 diabetes mellitus has evolved in the present century toward safer and more effective treatments, which in some cases can also reduce the risk of hypoglycemia, cardiovascular disease and renal outcomes.  New glucose-lowering drugs acting on novel pathways, as well as new formulations, have been developed, licensed and launched, many of which provide new options for the management of type 2 diabetes.  However, there is a rising prevalence of type 2 diabetes and its associated comorbidities, posing new challenges for health care practitioners.  These challenges are that much more demanding during the unprecedented COVID-19 pandemic.

This interactive webinar will review the novel mechanisms of action and pharmacokinetics of these agents and will also address how reaching appropriate therapeutic goals for the type 2 diabetes patient is possible. Four short presentations by prominent leaders in the fields of endocrinology and cardiology will focus on topics that will enable practitioners to implement new therapeutic strategies. To read more about the content to be presented, check out the blog entries and submit your comments and questions. These will be addressed during the live webinar during the question-and-answer session.

LEARNING OBJECTIVES
Based on the information presented during this live program, upon the webinar’s conclusion participants will be able to:
  • Recognize the association between glycemic variability as a predictor of hypoglycemia, the clinical
    implications of hypoglycemia in type 2 diabetes patients, and proven approaches to its prevention
  • Explain the role of fixed dose combination therapy and when and how it is appropriate to adjust insulin therapy in type 2 diabetes patients, as well as manage clinical inertia
  • Implement new treatment strategies with evidence provided by recent cardiovascular outcomes trials that highlight new therapies that have a demonstrated decrease in cardiovascular risk
  • Understand the special considerations for patients with type 2 diabetes in light of the COVID-19 pandemic
PROGRAM AGENDA
Presentation Speaker
20:00 – 20:05 Introduction and Program Objectives Andrew J.M. Boulton, MD, DSc, FICP, FACP, FRCP (Chair)
Manchester, England, UK
20:05 – 20:20 Proven Approaches to Preventing Hypoglycemia Brian Frier, BSc, MD, FRCP(Edin)
Edinburgh, Scotland, UK
20:20 – 20:35 Fixed Dose Combinations and Other Strategies to Managing Type 2 Diabetes Abdullah Bennakhi, MD
Kuwait City, Kuwait
20:35 – 20:50 The Impact of Uncontrolled Type 2 Diabetes on Overall Cardiovascular Health Naveed Sattar, MD
Glasgow, Scotland, United Kingdom
20:50 – 21:05 New Type 2 Diabetes Treatment Options: Optimizing Results Amidst the COVID-19 Pandemic Shashank Joshi, MD,DM,FRCP,FACE,FACP, FICP, FICN
Mumbai, Maharashtra, India
21:05 – 21:20 Live Discussion of Questions Submitted per Worldwide Diabetes-IFM Pre-Webinar Blog Moderated by the webinar chair
21:20 – 21:30 Panel Discussion / Question & Answer Session All Speakers
MEET THE FACULTY
Andrew J.M. Boulton, MD, DSc, FICP, FACP, FRCP (Program Chair)
Professor of Medicine, University of Manchester and
Consultant Physician, Manchester Royal Infirmary
Manchester, England, United Kingdom
Visiting Professor of Medicine, University of Miami Miller School of Medicine
Miami, Florida, United States
Chairman, EURADIA (The European Alliance for Diabetes Research)
President, International Diabetes Federation
Member of the Board of Directors, Worldwide Initiative for Diabetes Education
Brian M. Frier, BSc, MD, FRCP(Edin)
Honorary Professor of Diabetes
BHF Centre for Cardiovascular Science
The Queen’s Medical Research Institute
University of Edinburgh
Edinburgh, Scotland, United Kingdom
Abdullah Bennakhi, MD
Consultant Physician Diabetologist
Chair of the Regulatory Affairs Office and Ethical Review Committee
Dasman Diabetes Institute
Kuwait City, Kuwait
Naveed Sattar, MD
Professor/Honorary Consultant
Cardiovascular & Medical Sciences
University of Glasgow
Glasgow, Scotland, United Kingdom
Shashank R. Joshi, MD, DM, FRCP, FACE, FACP, FICP, FICN
Professor and Senior Consultant
Lilavati Hospital
Mumbai University
Mumbai, Maharashtra, India
This program is sponsored by the Worldwide Initiative for Diabetes Education and supported by an educational grant from Novo Nordisk A/S.